& Events
& Events
News
& Events
Inversago Pharma continues to rapidly expand its leadership team and appoints Glenn D. Crater, MD, FCCP as Chief Medical Officer
MONTREAL (CANADA) – November 30, 2020 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has appointed Glenn D. Crater, MD, FCCP as its Chief Medical Officer. In this position, Dr. Crater will oversee the clinical development of Inversago’s lead compound for Prader-Willi syndrome, INV-101, as well as […]
Inversago Pharma Appoints Michael D. Harvey, PhD as Senior Vice President, Drug Development
MONTREAL (CANADA) – October 13, 2020 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has appointed Michael D. Harvey, PhD as Senior Vice President, Drug Development. In his position, Dr. Michael Harvey will be responsible for overseeing all R&D activities pertaining to CMC, nonclinical development, and regulatory […]
Inversago Pharma Initiates Clinical Trials, with a Phase 1 study of INV-101, the Company’s Lead Peripheral CB1 Blocker
MONTREAL (CANADA) – September 29, 2020 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has initiated a Phase 1 clinical trial of INV-101, the Company’s peripherally-acting CB1 blocker, which is being developed for the treatment of Prader-Willi syndrome (PWS) and non-alcoholic steatohepatitis (NASH). The trial will evaluate […]
Media talk about Inversago Pharma
MONTREAL (CANADA) – September 28, 2020 – The Globe & Mail, BioteCanada’s Insights magazine and Endpoints News recently published articles about Inversago Pharma. The Globe & Mail – Investors bet $35-million on Montreal startup’s effort to revive failed class of weight-loss drugs by Sean Silcoff Insights Magazine – Fall 2020, Pages 80-81 – The Peripheral […]
